.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX07_Cabozantinib.Cabozantinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX07_Cabozantinib.Cabozantinib| name: | Cabozantinib |
| ATC code: | L01EX07 | route: | oral |
| n-compartments | 2 |
Cabozantinib is an oral multi-kinase inhibitor that targets MET, VEGFR, and other tyrosine kinases. It is approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.
Pharmacokinetic parameters reported in adult patients with advanced solid tumors. Parameters from population pharmacokinetic analyses in clinical studies involving both male and female patients.
Miles, D, et al., & Nguyen, L (2016). Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis. Clinical pharmacokinetics 55(1) 93–105. DOI:10.1007/s40262-015-0295-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/26149244
Castellano, D, et al., & Jonasch, E (2020). Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. Cancer treatment reviews 89 102062–None. DOI:10.1016/j.ctrv.2020.102062 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32659623
Tran, BD, et al., & Roskos, L (2023). Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. Cancer chemotherapy and pharmacology 91(2) 179–189. DOI:10.1007/s00280-022-04500-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36625894